首页> 美国卫生研究院文献>Virology Journal >Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening
【2h】

Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening

机译:根据国际乳头瘤病毒DNA检测宫颈癌筛查要求的国际准则对宫颈样品进行HPVIR高危HPV检测的临床验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe indicating FTA card is a dry medium used for collection of cervical samples. HPVIR is a multiplex real-time PCR test that detects 12 high-risk human papillomavirus types (hrHPV) and provides single genotype information for HPV16, − 31, − 35, − 39, − 51, − 56, and − 59 and pooled type information for HPV18/45 and HPV33/52/58. The aim of this study was to evaluate whether a strategy with cervical samples collected on the FTA card and subsequently analysed with the HPVIR test complies with the criteria of the international guidelines for a clinically validated method for cervical screening.
机译:背景技术指示性FTA卡是用于收集宫颈样本的干燥介质。 HPVIR是一项多重实时PCR测试,可检测12种高危型人乳头瘤病毒(hrHPV)并提供HPV16,-31,-35,-39,-51,-56和-59和合并型的单基因型信息有关HPV18 / 45和HPV33 / 52/58的信息。这项研究的目的是评估在FTA卡上收集并随后用HPVIR测试分析的宫颈样本的策略是否符合临床验证的宫颈筛查方法国际准则的标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号